N/A N=1

Prostate Cancer Screening in Men With Germline BRCA2 Mutations

Prostate Cancer

Bottom Line

View on ClinicalTrials.gov: NCT02154672 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2021

Primary outcome: Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 30+ yrs
Sex: Male
Sponsor: Yale University
Primary completion: Nov 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Prostate Cancer Patients With BRCA2 Mutation Carriers	—	—

Summary

The purpose of this study is to determine the incidence of prostate cancer in men with the BRCa2 gene mutation as an independent indicator for prostate cancer screening.

Eligibility Criteria

Inclusion Criteria

All men ≥30 years of age with at least a ten-year life expectancy
A known BRCA2 mutation
Ability to have an MRI
Able to give informed consent will be approached to participate in the study

Exclusion Criteria

If a man has received or is currently receiving treatment for prostate cancer

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02154672). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.